APICHOPE PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.64 CNY | -2.11% |
|
+3.96% | -20.75% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,339 | 10,200 | 9,894 | 13,394 | 10,615 | - | - |
| Enterprise Value (EV) 1 | 6,339 | 10,200 | 9,894 | 13,394 | 10,615 | 10,615 | 10,615 |
| P/E ratio | 28.1 x | 33.6 x | 36.2 x | 71 x | 45.5 x | 20.7 x | 28.3 x |
| Yield | - | - | 0.58% | 0.7% | 0.42% | 0.55% | - |
| Capitalization / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.74 x | 2.6 x | 2.74 x |
| EV / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.74 x | 2.6 x | 2.74 x |
| EV / EBITDA | - | - | 26.7 x | 34.4 x | 17 x | 13 x | 14.2 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 5.12 x | 5.37 x | 3.98 x | 3.28 x | 3.36 x |
| Nbr of stocks (in thousands) | 425,993 | 426,174 | 429,162 | 449,027 | 449,027 | - | - |
| Reference price 2 | 14.88 | 23.93 | 23.05 | 29.83 | 23.64 | 23.64 | 23.64 |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,675 | - | 2,280 | 2,503 | 2,836 | 4,077 | 3,878 |
| EBITDA 1 | - | - | 369.9 | 389.8 | 624.5 | 816.8 | 748.7 |
| EBIT 1 | - | - | 282 | 213.9 | 256.5 | 576.7 | 432.2 |
| Operating Margin | - | - | 12.37% | 8.55% | 9.05% | 14.15% | 11.14% |
| Earnings before Tax (EBT) 1 | - | - | 326.4 | 244.2 | 297.2 | 599.3 | 472.8 |
| Net income 1 | - | 306.9 | 290.7 | 184.6 | 237 | 514.2 | 377.7 |
| Net margin | - | - | 12.75% | 7.37% | 8.36% | 12.61% | 9.74% |
| EPS 2 | 0.5296 | 0.7133 | 0.6373 | 0.4200 | 0.5200 | 1.143 | 0.8350 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.1333 | 0.2100 | 0.1000 | 0.1300 | - |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 14.6% | 8.14% | 7.99% | 15.3% | 10.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | 8.63% | 9.7% | - |
| Assets 1 | - | - | - | - | 2,745 | 5,301 | - |
| Book Value Per Share 2 | - | - | 4.500 | 5.550 | 5.940 | 7.220 | 7.040 |
| Cash Flow per Share 2 | - | - | 1.100 | 1.010 | 1.370 | 1.620 | 1.530 |
| Capex 1 | - | - | 606 | 334 | 276 | 291 | 529 |
| Capex / Sales | - | - | 26.56% | 13.36% | 9.72% | 7.13% | 13.63% |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
23.64
CNY
Average target price
32.98
CNY
Spread / Average Target
+39.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.75% | 1.47B | |
| +18.94% | 43.74B | |
| +21.99% | 22.26B | |
| +16.41% | 14.9B | |
| +8.71% | 13.39B | |
| +40.72% | 12.12B | |
| -9.64% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.47B |
- Stock Market
- Equities
- 300723 Stock
- Financials ApicHope Pharmaceutical Co., Ltd